Does Insurance Cover GLP-1 for Fatty Liver? MASH Rules and Appeals

Whether insurance covers a GLP-1 medication for fatty liver depends almost entirely on how advanced your liver disease is. Since August 15, 2025, Wegovy (semaglutide) has held FDA approval for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, and major commercial insurers have built prior authorization pathways around that approval.1FDA. FDA Approves Treatment for Serious Liver Disease Known as MASH If you have the milder form of fatty liver without significant scarring, no GLP-1 is FDA-approved for your condition, and insurers almost always decline to cover one unless you also qualify under a separate diagnosis like type 2 diabetes or obesity.

Which Diagnosis You Have Decides Everything

Fatty liver sits on a spectrum. The milder form, metabolic dysfunction-associated steatotic liver disease (MASLD), is fat buildup without meaningful inflammation or scarring. MASH is the more serious stage, with inflammation and fibrosis that can progress to cirrhosis. Insurers draw a hard line between the two.

Wegovy’s August 2025 approval is specifically for adults with MASH and moderate-to-advanced fibrosis staged F2 or F3, and it rests on interim results from the phase 3 ESSENCE trial, where 63% of participants on Wegovy achieved MASH resolution without worsening scarring at 72 weeks, versus 34% on placebo.2Applied Clinical Trials Online. Semaglutide Steatohepatitis Fibrosis MASH The approval remains contingent on longer-term data, with results expected around 2028.3Hepatology (LWW). Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis

No GLP-1 is approved for the broader category of fatty liver (MASLD) without significant fibrosis. That gap is why coverage for earlier-stage patients is so hard: insurers generally tie coverage to FDA-approved indications, and off-label use for a liver condition rarely clears prior authorization.

What Commercial Plans Require When They Do Cover It

Major commercial insurers now have specific MASH policies for Wegovy, and the criteria are strict but consistent. Highmark requires that the prescriber be a gastroenterologist or hepatologist and that the patient have confirmed MASH with F2 or F3 fibrosis documented by liver biopsy within three years, or by a noninvasive test like FibroScan or MRE within six months. Patients must also show at least one cardiometabolic risk factor, evidence of lifestyle changes, and low alcohol use. Initial authorization lasts six months, with twelve-month renewals if fibrosis has stabilized or improved.4Highmark. Pharmacy Policy Bulletin J-1379

Cigna’s policy, effective May 2026, requires F2 or F3 fibrosis confirmed by biopsy, VCTE, MRE, or an Enhanced Liver Fibrosis (ELF) test, along with a managed metabolic risk factor and a specialist prescriber. Initial approval runs one year, and Cigna does not require patients to try Rezdiffra first.5Cigna. Coverage Position Criteria – Hepatology MASH Wegovy UnitedHealthcare also covers Wegovy for MASH with F2 or F3 fibrosis starting May 2026, with five-month initial authorization and twelve-month reauthorizations that require a positive clinical response and confirmation the patient has not progressed to cirrhosis.6UnitedHealthcare. Clinical Pharmacy Programs – Wegovy

Expect to supply the following in any prior authorization package:

  • ICD-10 diagnosis code K75.81 for NASH/MASH. Using an obesity code (E66.x) can trigger a weight-loss exclusion and result in denial.
  • Fibrosis staging showing F2 or F3, from biopsy within three years or FibroScan/MRE within six months.
  • Clinical confirmation that the patient does not have F4 fibrosis or decompensated cirrhosis.
  • At least one documented cardiometabolic condition, such as elevated BMI, type 2 diabetes, hypertension, or abnormal lipids.
  • Evidence of counseling on, or participation in, diet and exercise changes.
  • Specialist involvement, usually a gastroenterologist or hepatologist.

The American Association for the Study of Liver Diseases (AASLD) published practice guidance in November 2025 supporting semaglutide for MASH and listing noninvasive test thresholds for patient selection, including VCTE of 8–15 kPa and ELF scores of 9.2–10.5 for F2-F3 fibrosis.7AASLD. AASLD Announces Update to MASLD Practice Guidance Citing this guidance in the prior authorization strengthens the medical necessity argument.

If You Have Milder Fatty Liver, Not MASH

Patients with MASLD and no significant fibrosis are in a much tougher position. Because no GLP-1 is FDA-approved for that condition, any prescription aimed at the liver is off-label, and insurers generally will not cover it on that basis alone.8SingleCare. Will Insurance Cover Ozempic for Fatty Liver

The practical workaround is to qualify under a different FDA-approved indication the patient also has. If you also have type 2 diabetes, Ozempic (semaglutide) is widely covered for that purpose. If you meet obesity criteria, Wegovy or Zepbound may be coverable for weight management, though obesity coverage is itself inconsistent. The liver benefit then comes as a secondary effect of treating the approved condition.9MyObesityTeam. Will Insurance Pay for Medication for Fatty Liver Disease

The approval numbers show how much that second diagnosis matters. One analysis estimated initial approval rates of 65% to 75% when a concurrent type 2 diabetes or obesity diagnosis supports the prescription under an existing FDA indication, compared with just 15% to 25% when fatty liver disease is the only qualifying condition.10GoodRx. GLP-1 Insurance Coverage

Medicare and Medicaid

Medicare’s rules are especially restrictive. Federal law prohibits Medicare Part D from covering drugs prescribed for weight loss, and Medicare has historically rarely covered GLP-1s for non-diabetes indications.11Penn LDI. Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic The MASH approval opens a potential pathway: because MASH is a distinct liver disease indication rather than weight loss, Part D plans may cover Wegovy when prescribed specifically for MASH, provided the drug is on the formulary and the patient meets the plan’s criteria.12WellCare. Does Medicare Cover Weight Loss Drugs Part D plans are expected to apply their own prior authorization and utilization management for this indication.13CMS. Medicare GLP-1 Bridge

One boundary worth naming: the temporary Medicare GLP-1 Bridge demonstration running July 1, 2026 through December 31, 2027, which offers certain GLP-1s at a $50 monthly copay, is limited to weight loss and weight maintenance and does not apply to patients prescribed these drugs for MASH.14Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026

Medicaid varies by state. Programs must cover FDA-approved GLP-1s for diabetes and cardiovascular indications but can exclude weight-loss drugs. As of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity, and four states recently eliminated that coverage due to budget pressures.15KFF. Medicaid Coverage of and Spending on GLP-1s California’s Medi-Cal Rx has moved early on the MASH indication: as of April 1, 2026, it eliminated prior authorization for Wegovy prescribed for noncirrhotic MASH, though claims must include ICD-10 codes K76.0 or K75.8, and the drug remains excluded for weight-loss use.16Medi-Cal Rx (DHCS). Changes to GLP-1 Drug Coverage – Wegovy Other states are still deciding.

If You’re Denied

Denials are common. Prior authorization requirements have expanded sharply: under Medicare Part D alone, the share of beneficiaries subject to prior authorization for GLP-1s jumped from fewer than 5% before 2024 to nearly 100% by 2025.11Penn LDI. Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic Get the written denial letter and identify the specific unmet criterion before resubmitting anything.

  • If the denial says “not medically necessary,” file an appeal with a letter from the prescribing specialist citing the specific test results that confirm F2-F3 fibrosis, the FDA approval, and the AASLD guidelines.
  • If “not on formulary,” request a formulary exception. Because Wegovy is the only FDA-approved GLP-1 for MASH, you can argue that no formulary alternative with this specific indication exists.
  • If a “weight-loss exclusion” was applied, confirm the prior authorization was submitted under K75.81 rather than an obesity code, and clearly distinguish the liver indication from weight management in appeal documentation.
  • If “step therapy” is required (for example, trying Rezdiffra first), document why that alternative is inappropriate for the patient or provide records of prior attempts.

You can also request a peer-to-peer review, in which the prescribing doctor speaks directly with the insurer’s medical reviewer. If internal appeals are exhausted, an external review by an independent physician is available and overturns denials roughly 35% to 40% of the time.17Claimable. Wegovy Fatty Liver MASH Insurance Coverage Guide and Appeal Watch the deadlines: commercial plans typically allow 180 days to appeal, Medicare Part D allows 60.18U.S. News Health. Navigating Insurance Coverage for GLP-1 Medications

What You’ll Pay and Where to Get Help

Even with coverage, out-of-pocket costs are often significant. Novo Nordisk offers a savings program for Wegovy that covers the MASH indication: commercially insured patients may pay as little as $25 per month, with maximum savings of $100 per month, and uninsured or non-covered patients can access a $349 per month self-pay option. Patients on Medicare, Medicaid, or other government insurance are not eligible for the savings card.19NovoCare. MASH Savings Offer

Uninsured patients who meet income requirements may qualify for Novo Nordisk’s Patient Assistance Program, which provides medication at no cost. Eligibility generally requires household income at or below 400% of the federal poverty level (200% for Ozempic specifically) and no private or commercial insurance.20NovoCare. Patient Assistance Program Foundations like the PAN Foundation offer copay assistance for insured patients who struggle with cost-sharing, though those grants require that the plan already covers the medication.21PAN Foundation. Obesity Disease Fund

If Your Insurance Comes Through Work

Employer-sponsored coverage is uneven. A 2025 KFF survey found that 19% of firms with 200 or more workers covered GLP-1s for weight loss, rising to 43% among firms with 5,000 or more employees, while a separate survey of self-funded employers found 60% do not cover GLP-1s at all and have no plans to start.22Health System Tracker. Perspectives From Employers on Costs and Issues Associated With Covering GLP-1 Agonists for Weight Loss Some employers are tightening eligibility, raising BMI thresholds, or requiring enrollment in lifestyle programs.

The MASH approval complicates the picture. Plans that exclude GLP-1s as “weight-loss drugs” may still cover Wegovy when prescribed for a liver disease diagnosis, since the two indications are distinct. If your plan documents are unclear, ask the pharmacy benefit manager directly how MASH prescriptions are handled, and get the answer in writing before your doctor submits the prior authorization.23Mercer. GLP-1 Considerations for 2026 – Your Questions Answered